| abstract |
Δ8- and Δ9-prostaglandine derivates are disclosed, having the formula (I), in which (a) represents the residues (b) or (c); R1 represents the groups (d), (e), COOR4 or CONHR?5; R2 and R3¿ represent each a hydrogen atom or a hydroxyl group, whereas the OH group may be in the α- or β-position; X is a CH¿2?-group, an O or S atom; W is hydrogen, -OR?6¿, halogen, -CN-, -NO¿2?, trifluoromethyl or COOR?6¿, and when R4 is hydrogen, their salts with physiologically tolerable bases. α-, β- or η-cyclodextrinclathrates are also disclosed, as well as liposome-encapsulated compounds having the formula (I), their process of production and their pharmaceutical use. |